En Es
Categories

Industry News

AI Software Platform Aims to Synthesize Biomedical Knowledge

By HospiMedica International staff writers
12 Jun 2018

Image: The nference AI platform is designed to assist scientists’ abilities to generate holistic data-driven and unbiased hypotheses in a rapid manner (Photo courtesy of Shutterstock).nference (Cambridge , MA, USA), which focuses on artificial intelligence (AI)-powered life sciences, is developing an AI software platform to synthesize the exponentially growing biomedical knowledge.

The nference team, comprised of successful serial tech entrepreneurs and leading clinical, data and research scientists trained at Massachusetts Institute of Technology (MIT) and Harvard Medical School, works closely with pharmaceutical partners to solve the challenges in drug discovery and clinical research. This includes the identification of emerging targets and signaling pathways for disease processes with unmet need, stratification of patients in clinical trials, and prioritization of life-cycle opportunities for drugs in development. The nference AI platform plays a central role in augmenting the scientists’ abilities to generate holistic data-driven and unbiased hypotheses in a rapid manner.

nference uses state-of-the-art neural networks (shallow and deep learning models) for real-time, automated extraction of knowledge from the scientific, regulatory and commercial body of literature. The platform enables a diverse set of applications ranging from R&D to commercial strategy and operations in the life sciences ecosystem. nference is making biomedical knowledge computable, and building its AI platform to serve as the connective fabric for various silos of information that exist across health care enterprises.

“Natural language is the connective fabric across all therapeutic areas and support functions of large pharmaceutical companies,” said Venky Soundararajan, Ph.D., Founder and Chief Scientific Officer of nference and Qrativ. “Our AI platform leverages an ensemble of modern neural networks to decode the structure of literature. This kernel helps establish concordance between context-rich unstructured corpora and deep biological insights from structured databases spanning genomics to real world evidence. This presents a paradigm shift toward hypothesis-free scientific research and AI-augmented R&D decision-making.”

“The nference AI technology is enabling an important step forward in digitizing biology. nference’s approach reimagines big pharma R&D by enabling entirely novel hypotheses to emerge from the triangulation of insights across traditionally siloed structured databases and unstructured text documents,” said Diego Miralles, M.D., scientific advisor to nference and former Head of Johnson & Johnson Innovation. “This powerful platform establishes nference as a leader in the ongoing development of AI-powered drug discovery.”

“In addition to empowering drug discovery, the nference AI technology has the potential to transform both early and late-stage clinical development by allowing trialists and pharmaceutical companies to better guide patient selection and sooner anticipate side effects of novel therapies,” said Michael Gibson, M.D, scientific advisor to nference and Chief Executive Officer of the Baim Institute (Formerly Harvard Clinical Research Institute) and PERFUSE Research Institute at Harvard Medical School.

Related Links:
nference



E-mail Print
FaceBook Twitter Google+ Linked in

Additional news

18 Oct 2018
Roche Launches Roche Healthcare Consulting
Roche (Basel, Switzerland) has launched Roche Healthcare Consulting, a specialized consulting service that aims to help leaders in laboratories, hospitals and other healthcare groups optimize their operational, clinical and financial performance.
Read More
18 Oct 2018
GE Healthcare and ESR Enter AI Partnership for ECR 2019
GE Healthcare (Chicago, IL, USA) and the European Society of Radiology (Vienna, Austria) will be partnering on artificial intelligence (AI) for the upcoming European Congress of Radiology (ECR) to be held in Vienna, Austria on February 27-March 3, 2019. The partnership will include joint sessions on AI and a dedicated space at GE Healthcare’s booth where visitors will be able to experience the AI transformation through interactive tools.
Read More
18 Oct 2018
AI-Based Approach Reduces False Positives in Mammography
A team of researchers from the University of Pittsburgh have developed an artificial intelligence (AI) approach based on deep learning convolutional neural network (CNN) that could identify nuanced mammographic imaging features specific for recalled but benign (false-positive) mammograms and distinguish such mammograms from those identified as malignant or negative.
Read More
18 Oct 2018
Global DR Detectors Market to Reach USD 2.7 Billion by 2026
The global digital radiography (DR) detectors market is projected to grow at a CAGR of 6.1% during 2018-2026 to reach a valuation of USD 2.71 billion by 2026, as an increase in the number of radiography tests performed each year, along with the introduction of new and advanced imaging equipment by key market players, drive the demand for DR detectors.
Read More
15 Oct 2018
AI Algorithm Uses Key Signatures to Predict Onset of AD
A team of researchers has designed an artificial intelligence (AI) algorithm that learns signatures from magnetic resonance imaging (MRI), genetics, and clinical data to accurately predict cognitive decline leading to Alzheimer’s disease. The algorithm can help predict whether an individual’s cognitive faculties are likely to deteriorate towards Alzheimer’s in the next five years.
Read More
15 Oct 2018
Breast Cancer Screening Machine Learning Software Receives CE Mark
A new deep learning-based breast cancer screening software has received the CE mark and will be launched within the UK’s National Health Service (NHS) and European healthcare systems. The software has been developed by Kheiron Medical Technologies, a start-up that combines novel deep learning methods, data science, and radiology expertise to enable diagnostics designed to detect cancers and improve patient outcomes.
Read More
15 Oct 2018
GE Healthcare to Implement First AI-Powered Hospital Command Centers
GE Healthcare is collaborating with hospital service providers in Europe and the US for implementing an artificial intelligence (AI)-powered command center to effectively and efficiently synchronize all elements of a patient's hospital experience. The AI-powered system will support caregivers to enhance patient safety, orchestrate seamless care delivery and get patients back home sooner.
Read More
11 Oct 2018
Scientists Use Machine Learning and MRI Scans to Predict Learning Difficulties
A team of scientists from the Medical Research Council (MRC) Cognition and Brain Sciences Unit at the University of Cambridge used machine learning - a type of artificial intelligence - with data from hundreds of children who struggle at school to identify clusters of learning difficulties, which did not match their previous diagnosis. According to the researchers, this reinforces the need for children to receive detailed assessments of their cognitive skills to identify the best type of support.
Read More
10 Oct 2018
Utilization of X-Ray Mammography Systems Expected to Increase
Over the last 20 years, hospitals and imaging centers in the developed economies have adopted X-ray mammography systems for the screening and diagnosis of breast cancer. This has resulted in a significant reduction in mortality and encouraged emerging countries to make investments in population-base, organized screening. These significant investments in mammography technology have paved the way for radiation safety, patient comfort and 3D imaging that enables precise tumor detection.
Read More
Copyright © 2000-2018 TradeMed.com. All rights reserved. | Terms And Conditions